RT Journal Article
SR Electronic
T1 YYB-101, a Humanized Antihepatocyte Growth Factor Monoclonal Antibody, Inhibits Ovarian Cancer Cell Motility and Proliferation
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 671
OP 678
DO 10.21873/anticanres.14818
VO 41
IS 2
A1 HYUN JUNG KIM
A1 KYUN HEO
YR 2021
UL http://ar.iiarjournals.org/content/41/2/671.abstract
AB Background/Aim: Hepatocyte growth factor (HGF) acts as a key regulator in promoting ovarian cancer metastasis. Previously, we observed that YYB-101, a humanized anti-HGF antibody, effectively inhibits ovarian cancer cell migration, invasion, and progression. Here, we evaluated the signaling mechanisms affected by YYB-101 that are important in ovarian cancer cell progression. Materials and Methods: Using cell migration, invasion and proliferation assays, we evaluated the effects of YYB-101 on A2780/luc and SKOV3 cells. The effects of YYB-101 on signaling molecules were determined by immunocytochemistry and immunoblot analysis. Results: YYB-101 inhibited HGF-induced ovarian cancer cell motility by down-regulating paxillin phosphorylation and actin-cytoskeleton rearrangement. Also, YYB-101 inhibited ovarian cancer cell proliferation by reducing c-MET phosphorylation and activating apoptosis in vitro and in vivo. These effects were significantly enhanced by combining YYB-101 treatment with paclitaxel, a standard chemotherapy drug. Conclusion: YYB-101 can be examined as a new therapeutic agent for the treatment of patients with ovarian cancer.